The Fly | BNGO

Unique Optical Genome Mapping (OGM) Technology: The Saphyr system offers high-resolution, genome-wide detection of large structural variations (SVs) that are often missed by traditional cytogenetics or next-generation sequencing (NGS).

Superior Structural Variation Detection Capabilities: Bionano's OGM provides high sensitivity and specificity for identifying complex genomic rearrangements, which are critical for understanding various genetic diseases and cancers.

Complementary to Existing Genomic Tools: OGM does not replace but rather complements NGS and microarray technologies, providing a more comprehensive view of the genome by specifically excelling at SV detection, filling a critical gap in genomic analysis.

Slow Clinical Adoption and Reimbursement Approval: Bionano Genomics faces challenges in securing widespread clinical adoption and obtaining favorable reimbursement decisions from healthcare payers, which is critical for its Saphyr and Stratys systems to gain traction in diagnostic settings.

Intense Competition from Established and Emerging Technologies: The company operates in a highly competitive landscape, facing pressure from traditional cytogenetic methods, established short-read sequencing platforms, and rapidly advancing long-read sequencing technologies that also detect structural variations.

Continued Financial Losses and Need for Further Funding: Bionano Genomics has a history of operating losses and may require additional capital raises in the future, which could lead to further shareholder dilution if not offset by increased revenues and profitability.